Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 24INDUSTRY 9OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Breast 2Head & Neck 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Tamoxifen 10Capecitabine 10Trastuzumab 9Docetaxel 9pyrotinib 7Exercise 7Control Groups 7Vinorelbine 6Paclitaxel 6Letrozole 6Gemcitabine 6Cyclophosphamide 6Carboplatin 6exemestane 5Indocyanine Green 5Anastrozole 5pertuzumab 4dalpiciclib 4Injections 4Fulvestrant 4Doxorubicin 4Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Epirubicin 3Drug Therapy 3Cisplatin 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × toripalimab × Breast × Clear all
NCT07540533 2026-04-20

2025-370

Henan Cancer Hospital

Phase 2 Recruiting
92 enrolled
Breast

Advanced Breast Cancer

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 2 Not yet recruiting
216 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡